Stacie Hudgens - Concepedia

Author

Stacie Hudgens

Health Outcomes Solutions (United States)ORCID

Also Known As

Hudgens, Stacie, S Hudgens, S. Hudgens, Stacie A Hudgens, Stacie A. Hudgens, Stacie Hudgens

175

Publications

Citations

H-Index

Concepts

All Affiliations

Health Outcomes Solutions (United States)Northwestern University NorthShore University HealthSystem The University of Texas MD Anderson Cancer Center Clinical Solutions

About

Stacie Hudgens is an author at Health Outcomes Solutions (United States) specializing in medicine, oncology, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.4K
2	Health Sciences	3	3	295
3	Nursing	2	2	54
4	Public Health	2	2	155
5	Education	1	1	29

Stacie Hudgens

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, The Lancet Oncology Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus Vorinostat	2018	621
Measuring the side effects of taxane therapy in oncology David Cella, Amy H. Peterman, Stacie Hudgens, Cancer	2003	282
Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen, Journal of Clinical Oncology	2003	208
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial Arndt Vogel, Shukui Qin, Masatoshi Kudo, The Lancet. Gastroenterology & hepatology Patient-reported OutcomesHepatologyMedicineClinical TrialsLenvatinib Versus Sorafenib	2021	139
Atherosclerotic risk factor reduction in peripheral arterial disease Mary Mcdermott, Elizabeth A. Hahn, Philip Greenland, Journal of General Internal Medicine Cardiovascular DiseasePeripheral Artery DiseaseArterial DiseasePublic HealthMedicine	2002	130
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial Fred Saad, David Cella, Ethan Basch, The Lancet Oncology Quality Of LifeUrologyHealth-related QualityMedicineCancer Management	2018	128
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial Amit M. Oza, Ursula A. Matulonis, Susanne Malander, The Lancet Oncology MedicineCancer ManagementGynecologyRecurrent Ovarian CancerNiraparib Versus Placebo	2018	123
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials John D. Sheppard, Avani Joshi, Keith A. Betts, JAMA Ophthalmology	2017	80
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant Stacie Hudgens, Lysbeth Floden, Michael Blackowicz, Journal of Affective Disorders	2020	70
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial Javier Cortés, Stacie Hudgens, Chris Twelves, Breast Cancer Research and Treatment	2015	69

Page 1